Immutep Terminates NSCLC Trial for Efti
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy IMMP?
Source: Yahoo Finance
- Trial Termination: Australian biotech Immutep has terminated its late-stage TACTI-004 study evaluating eftilagimod alfa in combination with Keytruda for non-small cell lung cancer (NSCLC) following an independent data monitoring committee's recommendation, indicating the combination is unlikely to meet primary survival endpoints, marking a significant setback for the company.
- Stock Price Plunge: Following the trial's outcome, Immutep's stock price plummeted over 80% from $2.76 at market close on March 12 to $0.55 at market open on March 13, reflecting a sharp decline in investor confidence that could impact the company's financing and research capabilities.
- Efficacy Concerns: While Immutep remains committed to advancing eftilagimod alfa, analysts have raised concerns about the drug's efficacy after the discontinuation of TACTI-004, particularly in the competitive frontline metastatic NSCLC market where strong immunotherapy options already exist.
- Future Outlook: CEO Marc Voigt stated that the company will conduct a comprehensive review of available data to assess next steps, and despite the challenges, analysts believe that eftilagimod alfa still holds potential in specific indications like head and neck cancer, which may provide new growth opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.350
Low
12.00
Averages
12.00
High
12.00
Current: 0.350
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns regarding the company's transparency and investor trust.
- Lawsuit Preparation: The firm is preparing a class action to seek compensation for investors who purchased Immutep securities without any upfront costs, which may encourage more affected investors to join the action and recover losses.
- Clinical Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial for non-small cell lung cancer based on recommendations from the Independent Data Monitoring Committee, leading to an 82.6% drop in stock price, reflecting market pessimism about the company's future prospects.
- Market Reaction: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28 to close at $0.48, indicating a significant loss of investor confidence in the company's governance and future development.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action where investors can participate without any out-of-pocket fees, indicating the firm's commitment to recovering losses for affected investors and enhancing its reputation in securities litigation.
- Firm's Strength: The Rosen Law Firm recovered over $438 million for investors in 2019 and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for allegedly issuing materially misleading business information, emphasizing the firm's commitment to protecting investor rights.
- Lawsuit Preparation: The firm is preparing a class action to recover losses for investors who purchased Immutep securities, allowing participation without any upfront fees, thereby lowering the barrier for affected investors to seek compensation.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting a pessimistic outlook from the market regarding the company's future.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Immutep Stock Plummets 90% After Phase III Trial Halt Recommendation
- Trial Halt Recommendation: Immutep's Independent Data Monitoring Committee recommended halting the Phase III TACTI-004 trial due to an interim futility analysis indicating the drug is unlikely to meet efficacy endpoints, resulting in an 80% to 90% stock price drop in a single session.
- Severe Investor Losses: The disappointing trial results have left Immutep shareholders facing significant financial losses, leading to a drastic decline in market confidence regarding the company's future prospects, which may trigger further stock price declines.
- Disclosure Investigation: Levi & Korsinsky is investigating whether Immutep failed to adequately disclose material information regarding the status and interim results of the TACTI-004 trial, potentially involving securities law violations, which has heightened investor anxiety.
- Uncertain Company Outlook: Despite previously stating strong operational progress in a 6-K filing dated January 30, 2026, the subsequent trial halt has raised doubts about Immutep's clinical development capabilities, potentially impacting future financing and partnership opportunities.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential issuance of materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On March 13, 2026, Immutep's stock price plummeted by $2.28 per ADR, or 82.6%, closing at $0.48, following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate without any upfront fees through a contingency fee arrangement, thereby reducing financial burdens on investors.
- Firm's Strength: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong expertise and track record in this field.
See More
Investigation into Immutep Limited for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Immutep Limited investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns over corporate governance.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial based on the Independent Data Monitoring Committee's recommendation, indicating that the drug's efficacy in non-small cell lung cancer patients did not meet expectations, which may impact the company's future R&D direction.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price fell by 82.44% to close at $0.48 per ADR, reflecting extreme pessimism in the market regarding the company's outlook.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, exacerbating investor concerns about corporate governance and financial health, potentially affecting its reputation and ability to raise capital in the market.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns regarding the company's transparency and investor trust.
- Lawsuit Preparation: The firm is preparing a class action to seek compensation for investors who purchased Immutep securities without any upfront costs, which may encourage more affected investors to join the action and recover losses.
- Clinical Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial for non-small cell lung cancer based on recommendations from the Independent Data Monitoring Committee, leading to an 82.6% drop in stock price, reflecting market pessimism about the company's future prospects.
- Market Reaction: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28 to close at $0.48, indicating a significant loss of investor confidence in the company's governance and future development.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action where investors can participate without any out-of-pocket fees, indicating the firm's commitment to recovering losses for affected investors and enhancing its reputation in securities litigation.
- Firm's Strength: The Rosen Law Firm recovered over $438 million for investors in 2019 and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for allegedly issuing materially misleading business information, emphasizing the firm's commitment to protecting investor rights.
- Lawsuit Preparation: The firm is preparing a class action to recover losses for investors who purchased Immutep securities, allowing participation without any upfront fees, thereby lowering the barrier for affected investors to seek compensation.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting a pessimistic outlook from the market regarding the company's future.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Immutep Stock Plummets 90% After Phase III Trial Halt Recommendation
- Trial Halt Recommendation: Immutep's Independent Data Monitoring Committee recommended halting the Phase III TACTI-004 trial due to an interim futility analysis indicating the drug is unlikely to meet efficacy endpoints, resulting in an 80% to 90% stock price drop in a single session.
- Severe Investor Losses: The disappointing trial results have left Immutep shareholders facing significant financial losses, leading to a drastic decline in market confidence regarding the company's future prospects, which may trigger further stock price declines.
- Disclosure Investigation: Levi & Korsinsky is investigating whether Immutep failed to adequately disclose material information regarding the status and interim results of the TACTI-004 trial, potentially involving securities law violations, which has heightened investor anxiety.
- Uncertain Company Outlook: Despite previously stating strong operational progress in a 6-K filing dated January 30, 2026, the subsequent trial halt has raised doubts about Immutep's clinical development capabilities, potentially impacting future financing and partnership opportunities.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Investigation Launched: Rosen Law Firm has announced an investigation into Immutep Ltd. (NASDAQ: IMMP) due to potential issuance of materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On March 13, 2026, Immutep's stock price plummeted by $2.28 per ADR, or 82.6%, closing at $0.48, following the Independent Data Monitoring Committee's recommendation to discontinue the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate without any upfront fees through a contingency fee arrangement, thereby reducing financial burdens on investors.
- Firm's Strength: The Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong expertise and track record in this field.
See More
Investigation into Immutep Limited for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of Immutep Limited investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns over corporate governance.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial based on the Independent Data Monitoring Committee's recommendation, indicating that the drug's efficacy in non-small cell lung cancer patients did not meet expectations, which may impact the company's future R&D direction.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price fell by 82.44% to close at $0.48 per ADR, reflecting extreme pessimism in the market regarding the company's outlook.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, exacerbating investor concerns about corporate governance and financial health, potentially affecting its reputation and ability to raise capital in the market.
See More
